Semaglutide’s CV benefits may be related to more than weight loss
Healio reports on an analysis of SELECT trial data, published in the European Heart Journal, covering 17,604 adults with overweight or obesity but no diabetes. Researchers reported that weight loss and other measured risk factors could not fully explain the cardiovascular benefit of semaglutide 2.4 mg versus placebo, with wide confidence intervals. A Cleveland Clinic physician called the findings hypothesis-generating and said weight loss is likely still predominant.
Why it matters: Relevant to Maryland adults with overweight or obesity but no diabetes who are weighing semaglutide, and to the clinicians who refer them for cardiovascular risk care.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to healio.com. October 14, 2026.
